Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma

Iñigo Tirapu, Eduardo Huarte, Cristiana Guiducci, Ainhoa Anna, Mikel Zaratiegui, Oihana Murillo, Alvaro Gonzalez, Carmen Berasain, Pedro Berraondo, Puri Fortes, Jesús Prieto, Mario P. Colombo, Lieping Chen, Ignacio Melero

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Artificially enforced expression of CD80 (B7-1) and CD86 (B7-2) on tumor cells renders them more immunogenic by triggering the CD28 receptor on T cells. The enigma is that such B7s interact with much higher affinity with CTLA-4 (CD152), an inhibitory receptor expressed by activated T cells. We show that unmutated CD80 is spontaneously expressed at low levels by mouse colon carcinoma cell lines and other transplantable tumor cell lines of various tissue origins. Silencing of CD80 by interfering RNA led to loss of tumorigenicity of CT26 colon carcinoma in immunocompetent mice, but not in immunodeficient Rag -/- mice. CT26 tumor cells bind CTLA-4Ig, but much more faintly with a similar CD28Ig chimeric protein, thus providing an explanation for the dominant inhibitory effects on tumor immunity displayed by CD80 at that expression level. Interestingly, CD80-negative tumor cell lines such as MC38 colon carcinoma and B16 melanoma express CD80 at dim levels during in vivo growth in syngeneic mice. Therefore, low CD80 surface expression seems to give an advantage to cancer cells against the immune system. Our findings are similar with the inhibitory role described for the dim CD80 expression on immature dendritic cells, providing an explanation for the low levels of CD80 expression described in various human malignancies.

Original languageEnglish
Pages (from-to)2442-2450
Number of pages9
JournalCancer Research
Volume66
Issue number4
DOIs
Publication statusPublished - Feb 15 2006

Fingerprint

Colon
Carcinoma
Neoplasms
Tumor Cell Line
Experimental Melanomas
T-Cell Antigen Receptor
Dendritic Cells
Immune System
Immunity
RNA
T-Lymphocytes
Cell Line
Growth
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tirapu, I., Huarte, E., Guiducci, C., Anna, A., Zaratiegui, M., Murillo, O., ... Melero, I. (2006). Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Research, 66(4), 2442-2450. https://doi.org/10.1158/0008-5472.CAN-05-1681

Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. / Tirapu, Iñigo; Huarte, Eduardo; Guiducci, Cristiana; Anna, Ainhoa; Zaratiegui, Mikel; Murillo, Oihana; Gonzalez, Alvaro; Berasain, Carmen; Berraondo, Pedro; Fortes, Puri; Prieto, Jesús; Colombo, Mario P.; Chen, Lieping; Melero, Ignacio.

In: Cancer Research, Vol. 66, No. 4, 15.02.2006, p. 2442-2450.

Research output: Contribution to journalArticle

Tirapu, I, Huarte, E, Guiducci, C, Anna, A, Zaratiegui, M, Murillo, O, Gonzalez, A, Berasain, C, Berraondo, P, Fortes, P, Prieto, J, Colombo, MP, Chen, L & Melero, I 2006, 'Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma', Cancer Research, vol. 66, no. 4, pp. 2442-2450. https://doi.org/10.1158/0008-5472.CAN-05-1681
Tirapu I, Huarte E, Guiducci C, Anna A, Zaratiegui M, Murillo O et al. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Research. 2006 Feb 15;66(4):2442-2450. https://doi.org/10.1158/0008-5472.CAN-05-1681
Tirapu, Iñigo ; Huarte, Eduardo ; Guiducci, Cristiana ; Anna, Ainhoa ; Zaratiegui, Mikel ; Murillo, Oihana ; Gonzalez, Alvaro ; Berasain, Carmen ; Berraondo, Pedro ; Fortes, Puri ; Prieto, Jesús ; Colombo, Mario P. ; Chen, Lieping ; Melero, Ignacio. / Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. In: Cancer Research. 2006 ; Vol. 66, No. 4. pp. 2442-2450.
@article{fcdfb08926c9474aba546220bf124495,
title = "Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma",
abstract = "Artificially enforced expression of CD80 (B7-1) and CD86 (B7-2) on tumor cells renders them more immunogenic by triggering the CD28 receptor on T cells. The enigma is that such B7s interact with much higher affinity with CTLA-4 (CD152), an inhibitory receptor expressed by activated T cells. We show that unmutated CD80 is spontaneously expressed at low levels by mouse colon carcinoma cell lines and other transplantable tumor cell lines of various tissue origins. Silencing of CD80 by interfering RNA led to loss of tumorigenicity of CT26 colon carcinoma in immunocompetent mice, but not in immunodeficient Rag -/- mice. CT26 tumor cells bind CTLA-4Ig, but much more faintly with a similar CD28Ig chimeric protein, thus providing an explanation for the dominant inhibitory effects on tumor immunity displayed by CD80 at that expression level. Interestingly, CD80-negative tumor cell lines such as MC38 colon carcinoma and B16 melanoma express CD80 at dim levels during in vivo growth in syngeneic mice. Therefore, low CD80 surface expression seems to give an advantage to cancer cells against the immune system. Our findings are similar with the inhibitory role described for the dim CD80 expression on immature dendritic cells, providing an explanation for the low levels of CD80 expression described in various human malignancies.",
author = "I{\~n}igo Tirapu and Eduardo Huarte and Cristiana Guiducci and Ainhoa Anna and Mikel Zaratiegui and Oihana Murillo and Alvaro Gonzalez and Carmen Berasain and Pedro Berraondo and Puri Fortes and Jes{\'u}s Prieto and Colombo, {Mario P.} and Lieping Chen and Ignacio Melero",
year = "2006",
month = "2",
day = "15",
doi = "10.1158/0008-5472.CAN-05-1681",
language = "English",
volume = "66",
pages = "2442--2450",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma

AU - Tirapu, Iñigo

AU - Huarte, Eduardo

AU - Guiducci, Cristiana

AU - Anna, Ainhoa

AU - Zaratiegui, Mikel

AU - Murillo, Oihana

AU - Gonzalez, Alvaro

AU - Berasain, Carmen

AU - Berraondo, Pedro

AU - Fortes, Puri

AU - Prieto, Jesús

AU - Colombo, Mario P.

AU - Chen, Lieping

AU - Melero, Ignacio

PY - 2006/2/15

Y1 - 2006/2/15

N2 - Artificially enforced expression of CD80 (B7-1) and CD86 (B7-2) on tumor cells renders them more immunogenic by triggering the CD28 receptor on T cells. The enigma is that such B7s interact with much higher affinity with CTLA-4 (CD152), an inhibitory receptor expressed by activated T cells. We show that unmutated CD80 is spontaneously expressed at low levels by mouse colon carcinoma cell lines and other transplantable tumor cell lines of various tissue origins. Silencing of CD80 by interfering RNA led to loss of tumorigenicity of CT26 colon carcinoma in immunocompetent mice, but not in immunodeficient Rag -/- mice. CT26 tumor cells bind CTLA-4Ig, but much more faintly with a similar CD28Ig chimeric protein, thus providing an explanation for the dominant inhibitory effects on tumor immunity displayed by CD80 at that expression level. Interestingly, CD80-negative tumor cell lines such as MC38 colon carcinoma and B16 melanoma express CD80 at dim levels during in vivo growth in syngeneic mice. Therefore, low CD80 surface expression seems to give an advantage to cancer cells against the immune system. Our findings are similar with the inhibitory role described for the dim CD80 expression on immature dendritic cells, providing an explanation for the low levels of CD80 expression described in various human malignancies.

AB - Artificially enforced expression of CD80 (B7-1) and CD86 (B7-2) on tumor cells renders them more immunogenic by triggering the CD28 receptor on T cells. The enigma is that such B7s interact with much higher affinity with CTLA-4 (CD152), an inhibitory receptor expressed by activated T cells. We show that unmutated CD80 is spontaneously expressed at low levels by mouse colon carcinoma cell lines and other transplantable tumor cell lines of various tissue origins. Silencing of CD80 by interfering RNA led to loss of tumorigenicity of CT26 colon carcinoma in immunocompetent mice, but not in immunodeficient Rag -/- mice. CT26 tumor cells bind CTLA-4Ig, but much more faintly with a similar CD28Ig chimeric protein, thus providing an explanation for the dominant inhibitory effects on tumor immunity displayed by CD80 at that expression level. Interestingly, CD80-negative tumor cell lines such as MC38 colon carcinoma and B16 melanoma express CD80 at dim levels during in vivo growth in syngeneic mice. Therefore, low CD80 surface expression seems to give an advantage to cancer cells against the immune system. Our findings are similar with the inhibitory role described for the dim CD80 expression on immature dendritic cells, providing an explanation for the low levels of CD80 expression described in various human malignancies.

UR - http://www.scopus.com/inward/record.url?scp=33644520242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644520242&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-1681

DO - 10.1158/0008-5472.CAN-05-1681

M3 - Article

VL - 66

SP - 2442

EP - 2450

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 4

ER -